Management of postpartum iron deficiency anemia: review of literature

Simple item page
dc.contributor.authorSaber, Mohameden_US
dc.contributor.authorKhalaf, Mohameden_US
dc.contributor.authorAbbas, Ahmed M.en_US
dc.contributor.authorAbdullah, Sayed A.en_US
dc.date.accessioned2020-10-16T07:52:55Z
dc.date.available2020-10-16T07:52:55Z
dc.date.issued2019-01
dc.description.abstractAnemia is a condition in which either the number of circulating red blood cells or their hemoglobin concentration is decreased. As a result, there is decreased transport of oxygen from the lungs to peripheral tissues. The standard approach to treatment of postpartum iron deficiency anemia is oral iron supplementation, with blood transfusion reserved for more server or symptomatic cases. There are a number of hazards of allogenic blood transfusion including transfusion of the wrong blood, infection, anaphylaxis and lung injury, any of which will be devastating for a young mother. These hazards, together with the national shortage of blood products, mean that transfusion should be viewed as a last resort in otherwise young and healthy women. Currently, there are many iron preparations available containing different types of iron salts, including ferrous sulfate, ferrous fumarate, ferrous ascorbate but common adverse drug reactions found with these preparations are mainly gastrointestinal intolerance like nausea, vomiting, constipation, diarrhoea, abdominal pain, while ferrous bis-glycinate (fully reacted chelated amino acid form of iron) rarely make complication. Two types of intravenous (IV) preparations available are IV iron sucrose and IV ferric carboxymaltose. IV iron sucrose is safe, effective and economical. Reported incidence of adverse reactions with IV iron sucrose is less as compared to older iron preparations (Iron dextran, iron sorbitol), but it requires multiple doses and prolonged infusion time. Intramuscular iron sucrose complex is particularly contraindicated because of poor absorption. It was also stated that when iron dextran is given intravenously up to 30% of patients suffer from adverse effects which include arthritis, fever, urticaria and anaphylaxis.en_US
dc.identifier.affiliationsDepartment of Obstetrics and Gynecology, Aswan University Hospital, Aswan, Egypten_US
dc.identifier.affiliationsDepartment of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypten_US
dc.identifier.citationSaber Mohamed, Khalaf Mohamed, Abbas Ahmed M., Abdullah Sayed A.. Management of postpartum iron deficiency anemia: review of literature. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2019 Jan; 8(1): 338-342en_US
dc.identifier.issn2320-1770
dc.identifier.issn2320-1789
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/206408
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume8en_US
dc.source.urihttps://dx.doi.org/10.18203/2320-1770.ijrcog20185450en_US
dc.subjectIron deficiencyen_US
dc.subjectIntravenous ironen_US
dc.subjectOral ironen_US
dc.subjectPostpartum anemiaen_US
dc.titleManagement of postpartum iron deficiency anemia: review of literatureen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrcog2019v8n1p338.pdf
Size:
187.76 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Reproduction, Contraception, Obstetrics and Gynecology